Bruker acquires a majority stake in Biognosys

Please login or
register
04.01.2023
Biognosys Peptide kits

The newly formed strategic partnership saw Bruker Corporation make a majority-ownership investment in Biognosys, the provider of mass spectrometry-based proteomics solutions. In addition to leveraging Bruker’s expertise to advance precision proteomics, Biognosys will retain its existing team and expand into the US.

ETH Spinoff Biognosys offers a portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery, TrueTarget, and TrueSignature platforms and flagship proteomics software Spectronaut. The solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. CRO services and proteomics software customers can thus uncover connections between genome, transcriptome, and phenotype to explore the static and dynamic nature of disease biology.

The company has announced a strategic partnership in which Bruker acquired a majority share in Biognosys. Financial details were not disclosed. Several of Biognosys’ earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys.

The collaboration is expected to create unique synergies between Biognosys’ versatile portfolio of proprietary proteomics services, software and kits, and Bruker’s pioneering timsTOF platform. Biognosys will access the timsTOF technology for deeper, unbiased high-precision proteomics not impaired by epitope cross-reactivity - all with higher throughput and excellent reproducibility. Moreover, following the strategic partnership, Biognosys plans to open its first advanced proteomics CRO services laboratory in  Massachusetts, United States. From now on, Biognosys’ biomarker and biopharma customers will benefit from additional services and presence in the US.

Co-Founder and CEO Oliver Rinner and his leadership team will continue to manage Biognosys. “We are pleased to partner with Bruker to leverage our unique synergies to enable customers to explore the depth of the proteome from early research to clinical development”, said Rinner. “We have worked closely with Bruker to support dia-PASEF high-throughput, deeper proteomics methods within our Spectronaut software. Biognosys remains committed to maintaining Spectronaut® as a high-performance vendor-agnostic proteomics software. We plan to establish our US CRO lab in Massachusetts using the timsTOF platform, so that our customers can benefit from multiple MS technologies.”

Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, said: “We are delighted to partner with Biognosys to expand our CRO business in the US. We have many common biomarker and biopharma customers, and even more potential customers may prefer a proteomics CRO services expert like Biognosys for rapid, highest quality and flexible insertion of proteomics into their biomarker or biopharma discovery and development. With the rapid scientific acceptance of dia-PASEF® workflows, our partnership offers a unique combination of proteomics applications and data-science expertise, which can benefit more biopharma and diagnostics companies in using unbiased proteomics for decision-making.”

(Press release/RAN)

0Comments

More news about

Biognosys AG

Company profiles on startup.ch

Biognosys AG

rss